California-based AI drug discovery company Athos Therapeutics has secured USD 35 million in a Series B funding round. The investors were not disclosed.
The proceeds will support the development of treatments for autoimmune diseases and cancer, with USD 10 million specifically allocated to develop treatments for inflammatory bowel disease (IBD).
Founded in 2019, Athos Therapeutics develops novel small-molecule precision therapeutics targeting autoimmune diseases and cancers using AI-based medicinal chemistry and computational platforms. It also maintains a database of clinical and molecular datasets to identify novel drug targets.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.